Bio-Rad Laboratories has signed an agreement to acquire certain diagnostic businesses of Biotest for 45 million euros, the terms of which were not disclosed. The transaction is subject to closing conditions, including regulatory approvals, and is expected to close in the first quarter of 2010.
Biotest develops, manufactures and markets pharmaceutical, biotherapeutic and diagnostic products. Integrating Biotest’s diagnostic business into Bio-Rad’s product portfolio will broaden the company’s offering in the area of immunohematology and provide Bio-Rad access to the US markets with a full range of products.
Phone: 0011 1 510 724 7000
Promega Paradyme 27GY STR System
The Paradyme 27GY STR System features a novel enzyme that reduces the most common type of...
Mercodia Insulin MBeads Assay
The assay is designed to offer high accuracy by specifically measuring human insulin while...
Waters BD FACSDiscover A7 Cell Analyzer
The BD FACSDiscover A7 Cell Analyzer combines high spectral resolution and sensitivity with...
